Nicox Receives Patent for NCX 470 in China, Extending Coverage to 2039

Nicox Receives Patent for NCX 470 in China, Extending Coverage to 2039

February 22, 2022

Nicox SA has received a formulation patent for NCX 470, its flagship pharmaceutical candidate in development for patients with open-angle glaucoma or ocular hypertension, from the Chinese National Intellectual Property Administration (CNIPA), extending coverage in China until 2039.

With the equivalent US and European patents already granted, the formulation is now covered in most major global territories. NCX 470 is also covered by granted composition of matter patents.

“The granting of this formulation patent in China, in addition to the recent European and United States grants, further strengthens the protection around our lead product candidate, NCX 470, and allows our partner in China, Ocumension Therapeutics, to benefit from a significantly longer period of exclusivity while securing Nicox’s royalty stream on sales in China," Gavin Spencer, Chief Business Officer at Nicox, said in a company news release.

"Our phase 3 clinical trials, Mont Blanc and Denali, continue to advance and we look forward to the submission of new drug applications in both the United States and China to bring NCX 470 to patients in these important markets.”

Nicox's flagship product candidate, NCX 470, is a new NO-donating prostaglandin analog that releases bimatoprost and NO into the eye.

NCX 470 is currently being evaluated against latanoprost, the leading prostaglandin analog by prescription volume in the US, in the ongoing Mont Blanc and Denali phase 3 clinical trials, with results expected in Q1 2023 and by the end of 2023, respectively.

In China, Korea, and Southeast Asia, Nicox has licensed exclusive rights to Ocumension for NCX 470. Nicox received €18 million in exchange for these rights while Ocumension is covering half of the overall cost of the Denali phase 3 clinical trial.

Nicox is set to receive a tier of royalties ranging from 6% to 12% on Ocumension's sales of NCX 470. Since July 2020, Ocumension has been a Chinese ophthalmology firm listed on the Hong Kong stock exchange.